Paraproteinämische Keratopathie als klinisches Zeichen einer monoklonalen Gammopathie

Zusammenfassung

Patienten mit monoklonaler Gammopathie können eine behandlungsbedürftige paraproteinämische Keratopathie (PPK) aufweisen. Die PPK muss gegenüber verschiedenen Formen von Hornhautdystrophie, einzelnen systemischen Stoffwechselstörungen mit Hornhautbeteiligung sowie gegenüber immunologischen und inflammatorischen Hornhauterkrankungen abgegrenzt werden.

Abstract

Patients with monoclonal gammopathy can show paraproteinemic keratopathy (PPK) with an indication to treatment. PPK has to be differentiated from corneal dystrophies, systemic metabolic disorders with corneal involvement, as well as from immunologic and inflammatory corneal diseases.

Schlüsselwörter

monoklonale Gammopathie unklarer Signifikanz (MGUS) - paraproteinämische Keratopathie (PPK) - Serumproteinelektrophorese - verschiedene korneale Trübungsformen der PPK - Fehldiagnosen der PPK - Häufigkeit der PPK

Key words

monoclonal gammopathy of undetermined significance (MGUS) - paraproteinemic keratopathy - serum protein electrophoresis - various corneal opacities of PPK - missed diagnosis of PPK - occurrence of PPK

• Literatur

• 1 OʼConnell TX, Horita TJ, Kasravi B. Understanding and interpreting serum protein electrophoresis. Am Fam Physician 2005; 71: 105-112
• 2 Kortüm M, Driessen C, Einsele H. et al. Multiples Myelom. Im Internet: https://www.onkopedia.com/de/onkopedia/guidelines/multiples-myelom/@@view/html/index.html Stand: 15.12.2016
• 3 Kyle RA. Monoclonal gammopathy of undetermined significance. Am J Med 1978; 64: 814-826
• 4 Eisele L, Dürig J, Hüttmann A. et al. Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany. Ann Hematol 2012; 91: 243-248
• 5 International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757
• 6 Kyle RA, Durie BGM, Rajkumar SV. et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma. IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24: 1121-1127
• 7 Dimopoulos MA, Kastritis E, Rosinol L. et al. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008; 22: 1485-1493
• 8 Steuhl K-P, Knorr M, Rohrbach JM. et al. Paraproteinemic corneal deposits in plasma cell myeloma. Am J Ophthalmol 1991; 111: 312-318
• 9 Bourne WM, Kyle RA, Bubaker RF. et al. Incidence of corneal crystals in the monoclonal gammopathies. Am J Ophthalmol 1989; 107: 192-193
• 10 Lisch W, Wasielica-Poslednik J, Kivelä T. et al. The hematologic definition of monoclonal gammopathy of undetermined significance in relation to paraproteinemic keratopathy (an American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc 2016; 114: T7
• 11 Kocabeyoglu S, Mocan MC, Haznedaroglu IC. et al. In vivo confocal microscopic characteristics of crystalline keratopathy in patients with monoclonal gammopathy: report of two cases. Indian J Ophthalmol 2014; 62: 938-940
• 12 Weiss JS, Moeller HU, Aldave AJ. et al. IC3D classification of corneal dystrophies – edition 2. Cornea 2015; 34: 117-159
• 13 Kyle RA, Therneau TM, Rajkumar SV. et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362-1369
• 14 Firkin FC, Lee N, Ramsay R. et al. Visual loss caused by corneal crystals in myeloma: rapid improvement and plasma exchange and chemotherapy. Med J Aust 1979; 2: 677-678
• 15 Høisen H, Ringvold A, Kildahl-Andersen O. Corneal crystalline deposits in multiple myeloma. A case report. Acta Ophthalmol (Copenh) 1983; 61: 493-500
• 16 Klintworth GK, Bredehoeft SJ, Reed JW. Analysis of corneal crystalline deposits in multiple myeloma. Am J Ophthalmol 1978; 86: 303-313